| Symbol | TLPPF |
|---|
| Name | TELIX PHARMACEUTICAL LTD. |
|---|
| Sector | HEALTH CARE |
|---|
| Region | Oceania |
|---|
| Industry | - |
|---|
| Address | 3051 Australia VA 55 Flemington Road Level 4, Suite 401 |
|---|
| Telephone | +61 3 3093 3897 |
|---|
| Fax | — |
|---|
| Email | — |
|---|
| Website | https://telixpharma.com/ |
|---|
| Incorporation | AU |
|---|
| Incorporated On | — |
|---|
| Employees | — |
|---|
| Fiscal Year | 12/31 |
|---|
| Public Since | — |
|---|
| Exchanges | OTC;NASDAQ |
|---|
| Auditor | — |
|---|
| Audit Status | AUDITED |
|---|
| Reporting Status | International Reporting: ASX - Australian Securities Exchange |
|---|
| CIK | — |
|---|
| Description | Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy.
Additional info from NASDAQ:
Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. Our mission is to be the global leader in radiopharmaceuticals by combining therapeutic and diagnostic modalities for the benefit of patients, an innovative precision medicine concept generally referred to as "theranostics". We have an extensive pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Our theranostic approach is intended to use imaging and therapy together to "see and treat" cancer and rare diseases, to both better inform treatment decisions and deliver personalized therapy for patients.
Additional info from OTC:
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. |
|---|
No clinical trials found for this company.
No clinical products found for this company.